Patent 9301923 was granted and assigned to Novartis on April, 2016 by the United States Patent and Trademark Office.
Disclosed are formulation and optimization protocols for delivery of therapeutically effective amounts of biologically active agents to liver, tumors, and/or other cells or tissues. Also provided are compositions and uses for cationic lipid compounds of formula (I).